Diabetic Macular Edema Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Indication Type (Diffuse Diabetic Macular Edema, Focal Diabetic Macular Edema), By Treatment (Laser Treatment, Intravitreal Steriods, Anti-angiogenic Drugs Injection, Anti-vascular Endothelial Growth Factor (VEGF) Therapy, Others), By End User (Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers), and Region  

Diabetic Macular Edema Treatment Market Size was valued at US$ 9.56 billion in 2022 and is poised to grow at a CAGR of 4.52% during 2023-29. Diabetic macular edema is a leading cause of vision impairment among people. Macular edema occurs when the fluid and proteins start collecting on or under the macula of the eye thereby resulting in swelling leading to distorted vision. Diabetic macular edema is a disease that is followed by diabetic retinopathy. Diabetic retinopathy is a condition that severely damages the blood vessels of the retina, resulting in vision defects or vision loss. These blood vessels, if left untreated, due to pressure in the eye result in fluid leakage, causing Diabetic Macular Edema (DME). An increase in the prevalence of diabetes is the major factor driving the growth of the global market.

The prevalence of diabetic macular edema is found to be higher in type 2 diabetes patients than in type 1 diabetes patients. In the projected period, new and creative research and development for the treatment of diabetic macular edema would likely increase the growth of the diabetic macular edema treatment market. On the other hand, advancements in ophthalmic surgery techniques and pharmaceutical firms' R&D investments would enhance numerous opportunities, resulting in the diabetic macular edema treatment market growing over the projection period. During the projected period, the diabetic macular edema treatment market is expected to be hampered by high medical costs for patients and frequent visits to physicians. There is no need for treatment in the early stages of DME unless the patients are able to keep their blood sugar levels under control. Laser photocoagulation is the standard treatment for diabetic macular edema if the condition becomes severe. This method involves administering a pattern of burns or cauterizing leaky blood vessels using a laser to minimize edema. Retinal experts use anti-vascular endothelial growth factor corticosteroid injections in combination with laser photocoagulation to avoid the treatment's negative effects. Only two approved medications for treating DME are now available on the market: Lucentis and Ozurdex. Clinical trials are now underway for other therapy options.